W. Kimryn Rathmell MD PhD

PubMed

• 11 citations
  Subset-specific mitochondrial stress and DNA damage shape T cell responses to fever and inflammation.
  Darren R Heintzman, Rachael C Sinard, Emilie L Fisher, Xiang Ye, Andrew R Patterson
  Science Immunology. 2024-09-20
• 4 citations
  A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).
  Edward Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon
  Cancer Research Communications. 2024-07-01
• 1 citations
  Author Correction: Obesity induces PD-1 on macrophages to suppress anti-tumour immunity.
  Jackie E Bader, Melissa M Wolf, Gian Luca Lupica-Tondo, Matthew Z Madden, Bradley I Reinfeld
  Nature. 2024-07-01

Journal Articles

• Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Ca...  
  Michael B Atkins, Mario Sznol, Robert J Motzer, Richard W Joseph, Thomas Hutson, John Hainsworth, W Kimryn Rathmell, Brian I Rini, David F McDermott, Toni K Choueiri, ..., Nature
• VHL Substrate Transcription Factor ZHX2 as an Oncogenic Driver in Clear Cell Renal Cell Carcinoma  
  Eric Jonasch, Xian Chen, William Y Kim, W Kimryn Rathmell, Science Magazine
• Epigenetic Modifiers: Activities in Renal Cell Carcinoma  
  W. Kimryn Rathmell, MD, Nature
• Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Carcinoma  
  Michael B Atkins, Thomas Hutson, Mario Sznol, Toni K Choueiri, Sumanta K Pal, Richard W Joseph, John Hainsworth, W Kimryn Rathmell, David F McDermott, Robert J Motzer,..., Nature
• A case report of severe type B lactic acidosis following first dose of nivolumab in a VHL-mutated metastatic renal cell carcinoma  
  Nakajima, E, Leger, P, Mauer, IA, Neuss, MN, Chism, DD, Rathmell, WK, Kidney Cancer, 1/1/2017
• Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas  
  Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, Imielinski M, Hu X, Ling S, Akbani R, Rosenberg M, Cibulskis..., Nat Genet, 1/1/2016
• Characterization of HPV and host genome interactions in primary head and neck cancers  
  Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, Lee S, Hadjipanayis AG, Ivanova EV, Wilkerson MD, Protopopov A, Yang L, Seth S, Song X, Tan..., Proc. Natl Acad. Sci. U S A., 1/1/2014
• The somatic genomic landscape of chromophobe renal cell carcinoma  
  Davis, CF*, Ricketts, C*, Wang, M*, Yang, L*, Cherniack, AD, Shen, H, Buhay, C, Kim, SC, Fahey, CC, Hacker, KE, Bhanot, G, Gordenin, DA, Chu, A, Gunaratne, PH, Biehl, ..., Cancer Cell., 1/1/2014
• Comprehensive molecular characterization of gastric adenocarcinoma  
  Cancer Genome Atlas Research Network., Nature, 1/1/2014
• ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma  
  Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Miller CR, Nielsen ME, Rathmell, WK, Eur Urol., 1/1/2014
• HIF1 and HIF2 exert differential preferences on nutrient utilization  
  Arreola, A, Cowey, CL, Coloff, J, Rathmell, JC, and Rathmell, WK., PLoS One., 1/1/2014
• Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects  
  Simon, J*, Hacker, KE*, Brannon, AR, Parker, JS, Weiser, M, Ho, TH, Kuan PF, Jonasch E, Furey TS, Prins JF, Lieb, JD**, Rathmell, WK**, Davis, IJ, Genome Research., 1/1/2014
• Seeing the Forest for the Trees: Kidney Oncogenomes Relate to Therapeutic Outcomes  
  Chism, DD, Rathmell, WK., Clin Cancer Res, 1/1/2014
• Racial Difference in Histologic Subtype of Renal Cell Carcinoma  
  Olshan, AF, Kuo, T, Meyer, A-M, Nielsen, ME, Purdue, MP, and Rathmell, WK, Cancer Med., 1/1/2013
• Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial  
  Stein A, Bellmunt J, Escudier B, Kim D, Stergiopoulos SG, Mietlowski W, Motzer RJ; RECORD-1 Trial Study Group., Eur Urol, 1/1/2013
• In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation  
  Gameiro PA, Yang J, Metelo AM, Pérez-Carro R, Baker R, Wang Z, Arreola A, Rathmell WK, Olumi A, López-Larrubia P, Stephanopoulos G, Iliopoulos O., Cell Metabolism, 1/1/2013
• FDG-PET as a Predictive Biomarker for Therapy with Everolimus in Metastatic Renal Cell Cancer (mRCC)  
  Chen, J, Appelbaum, D, Kocherginsky, M, Cowey, CL, Rathmell, WK, McDermott, D, Stadler, W, Cancer Med, 1/1/2013
• Pleiotropic Effects of the Trichloroethylene-Associated P81S VHL Mutation on Metabolism, Apoptosis and ATM-Mediated DNA Damage Response  
  DeSimone, M, Rathmell, WK*, Threadgill, D*, J. Natl. Cancer Inst, 1/1/2013
• Ror2 creates a poised signal for Wnt signaling in renal cell carcinoma  
  Rasmussen, N, Wright, T,Debebe, Z, Hacker, KE, Sen, O, Major, MB, Green, J., Wahl, G, Rathmell, WK, J Biol Chemistry, 1/1/2013
• Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors  
  Cancer, 1/1/2010
• The importance of HIF in clear cell renal cell carcinoma  
  Rathmell, WK, Kidney Cancer Journal., 1/1/2009
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial  
  Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; R..., Lancet, 1/1/2008
• Biomarkers guide choice in systemic treatment  
  Rathmell, WK., Kidney Cancer Journal., 1/1/2008
• Genomics of chromophobe renal cell carcinoma: implications from a rare tumor for pan-cancer studies  
  Rathmell KW*, Chen F, Creighton CJ, Oncoscience, 1/20/2015
• Von Hippel-Lindau status influences phenotype of liver cancers arising from PTEN loss  
  Sendor AB, Hacker KE, Chen S, Corona AL, Sen O, Chiang DY, Snavely A, Rogers AB, Montgomery SA, Rathmell WK, McRee AJ., Gastrointest Cancer., 1/1./2015
• Join now to see all

Books/Book Chapters

• Renal Cell Carcinoma: Principles and Practice 
  Chapter: Biomarkers for Renal Cell Carcinoma 
  Rose, T and Rathmell, WKEditors: Primo Lara and Eric Jonasch.Edition 2nd,2015
• 9th Manual of Clinical Oncology 
  Chapter: Kidney Cancer 
  Ferguson, JE, Wallen, EM, and Rathmell, WK2014
• Renal Cell Carcinoma 
  Chapter: Prognostic and Predictive Biomarkers in Renal Cell Carcinoma (RCC) 
  Chism, DD and Rathmell, WKEditors: Nizar Tannir.2014
• Renal Cell Carcinoma: Biology, Prognostic Factors, and Therapeutic Targets. 
  Chapter: HIF biology in renal cell carcinoma 
  Rathmell, WK.Editors: Robert Figlin, Brian Rini, and W. Kimryn Rathmell.2012
• Renal cell carcinoma: clinical management 
  Chapter: Biology of RCC (VEGF, mTOR, immune aspects). 
  Arreola, A and Rathmell, WK.Editors: Brian Rini and Stephen Campbell..2012
• ASCO Education Book 
  Chapter: Biomarkers in renal cell carcinoma 
  Li, M and Rathmell, WK2011
• Emerging Cancer Therapeutics: Renal Cancer. 
  Chapter: The biology of renal cell carcinoma. 
  Page 1.0 - 20.0Haake, SM and Rathmell, WKEditors: Walter Stadler and Jame Abraham.2011
• Renal cell carcinoma: Principles and Practice. 
  Chapter: Biomarkers for renal cell carcinoma. 
  Li, M and Rathmell, WKEditors: Primo Lara and Eric Jonasch.2011
• Kidney Cancer. 
  Chapter: Basic Research in Kidney Cancer. 
  Oosterwijk, E, Belldegrun, A, Brannon, AR, Finley, DS, Junker, K, Pouliot, F, Rathmell, WK and Uemura, H.Editors: Z. Kirkali and P. Mulders.1st EAU-ICUD International Consultation on Kidney Cancer, Barcelona2010
• Medical Biostatistics for Complex Diseases 
  Chapter: Predicting Cancer Survival Using Expression Patterns 
  Page 305.0 - 330.0Reddy, A, Kronek, L-P, Brannon, AR, Seiler, M, Ganesan, S, Rathmell, WK, Bhanot, G.Editors: Emmert-Streib, F. and Dehmer, M..2010
• Renal Cell Carcinoma 
  Chapter: Vascular Endothelial Growth Factor Ligand-Binding Agents. 
  Page 203.0 - 210.0Rini, BI and Rathmell, WKEditors: Rini, B. and Campbell, S..2009
• Renal Cell Carcinoma 
  Chapter: Angiogenesis Biology in Metastatic Renal Cell Carcinoma. 
  Page 191.0 - 202.0Amin, C and Rathmell, WKEditors: Rini, B. and Campbell, S..2009
• Renal Cell Carcinoma 
  Chapter: Biologic and Clinical Implications of VEGF Activity in Renal Cell Carcinoma. 
  Page 99.0 - 118.0Rathmell, WK and Rini, BI.Editors: Bukowski, R., Motzer, R., and Figlin, R..2008
• Netter’s Internal Medicine 
  Chapter: Testicular Cancer. 
  Page 614.0 - 622.0Rathmell, WK and Godley, PEditors: Runge, M. and Greganti, A..Edition 2nd,2008
• ASCO Education Book 
  Chapter: Rational Therapeutic Choices and Strategies for Patients with Metastatic Renal Cancer 
  Rathmell, WK, Stadler, WM, Rini, BI.2008
• ASCO Education Book 
  Chapter: VHL Gene: Clinical Implications 
  Rathmell, WK2007
• DNA damage and repair, Vol. 2: DNA repair in higher eukaryotes 
  Chapter: Mechanisms for DNA double-strand break repair in eukaryotic cells. 
  Page 299.0 - 316.0Rathmell, WK, Chu, G.Editors: Nickolof, J.A., Hoekstra, M.F..Humana Press1998
• Join now to see all

Lectures

• Renal Cell Carcinoma. 
  Nashville, TN - 1/1/2016
• Translational Research at the Bioinformatic Edge. 
  Schloss Dagstuhl, Wadern, Germany - 1/1/2016
• Renal Medullary Carcinoma 
  Nashville, TN - 1/1/2016
• Chromatin and transcriptional regulation in RCC 
  Duke-NUS Singapore. - 1/1/2016
• ClearCode34, is it ready for prime time? 
  St. Andrews, Scotland. - 1/1/2016
• Translational Studies in RCC. 
  Vanderbilt University. - 1/1/2016
• Alterations in angiogenesis related to VHL mutation. 
  Houston, TX - 1/1/2016
• What Nephrologists should know about kidney cancer 
  Sand Diego, CA - 1/1/2015
• New Directions in RCC 
  Lake Geneva, WI - 1/1/2015
• Balancing the career of an MD-PhD 
  Wrightsville Beach, NC. - 1/1/2015
• Targeting Notch pathway to overcome resistance to anti-angiogenic therapy in RCC 
  MD Anderson Cancer Center, Ann, Houston, TX - 1/1/2015
• Epigenetics in Kidney Cancer. 
  New Orleans, LA - 1/1/2015
• Comparison of kidney cancers using The Cancer Genome Atlas. 
  Chapel Hill, NC - 1/1/2015
• Angiogenic and Metabolic Phenotypes in RCC 
  ChongQing, China. - 1/1/2015
• Using Kidney tissue to make disease assessment. 
  NIDDK, Bethesda, MD - 1/1/2015
• SETD2 Mutations in Clear Cell RCC. 
  Bethesda, MD - 1/1/2014
• Transcriptomics of VHL disease 
  Madrid, Spain - 1/1/2014
• Renal Cell Carcinoma Translational Opportunities 
  Weissman Institute, Rehovot, Israel - 1/1/2014
• A Predictor for Survival in Intermediate Grade Clear Cell Renal Cell Carcinoma. 
  1/1/2009
• Renal cell carcinoma: update 2009 
  Reno, NV. - 1/1/2009
• Renal Cell Carcinoma: a new era of targeted therapy 
  Maine Medical Center. Silver Springs MD, Birmingham, AL, Laurinberg, NC, Hendersonville, NC - 1/1/2008
• Focus on Fellows and Junior Faculty, Participation in the annual meeting. 
  1/1/2005
• Animal Modeling of RCC 
  University of North Carolina - 1/1/2005
• VHL: Oxygen sensing and molecular targeting 
  Hilton Head, SC - 1/1/2004
• Multidisciplinary Advances in the Treatment of Genitourinary Cancers 
  University of North Carolina at Chapel Hill - 1/1/2004
• Join now to see all

Other

• Tumor Genomics Program 
  Rathmell, WK
  http://university.asco.org/tumor-genomics-program
  ASCO University. - 1/1/2014
• Comment on autophagy related to VHL gene as a strategy to develop cancer treatments 
  Rathmell, WK, NPR Morning Edition.
  1/1/2008
• mTOR: An Emerging Pathway in Cancer 
  Rathmell, WK. and Shaw R., Novartis Internal Training Module.
  1/1/2008
• Kidney cancer. An Interview with Dr. Kimryn Rathmell 
  Draznin, J.
  www.Oncolink.com
  1/1/2004
• Keystone Symposia, Mouse Models of Human Cancer Meeting Review. 
  Rathmell, WK., and Van Dyke, T., Investigational Drugs Database. Thomson Current Drugs Online
  1/1/2004
• Thesis, Ku and DNA/PK in the repair of DNA double strand breaks 
  Rathmell, WK, Stanford University
  1/1/1996
• Making Strides Against a Rare Disease: Renal Medullary Carcinoma in Focus. 
  Rathmell, WK, OncLive.
  1/8./2017
• Join now to see all